This Key Event Relationship is licensed under the Creative Commons BY-SA license. This license allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
Relationship: 1926
Title
GSK3beta inactivation leads to β-catenin activation
Upstream event
Downstream event
AOPs Referencing Relationship
Taxonomic Applicability
| Term | Scientific Term | Evidence | Link |
|---|---|---|---|
| Homo sapiens | Homo sapiens | High | NCBI |
Sex Applicability
| Sex | Evidence |
|---|---|
| Unspecific | High |
Life Stage Applicability
| Term | Evidence |
|---|---|
| All life stages | High |
GSK3beta inactivation leads to beta-catenin dephosphorylation, which avoids the ubiquitination of the beta-catenin and stabilize the beta-catenin (Clevers & Nusse, 2012).
| ID | Experimental Design | Species | Upstream Observation | Downstream Observation | Citation (first author, year) | Notes |
|---|
| Title | First Author | Biological Plausibility |
Dose Concordance |
Temporal Concordance |
Incidence Concordance |
|---|
Biological Plausibility
Dose Concordance Evidence
Temporal Concordance Evidence
Incidence Concordance Evidence
Uncertainties and Inconsistencies
GSK3beta phosphorylates LRP6 as well as remaining GSK3 beta phosphorylates beta-catenin which would be ubiquitinated and degradated (MacDonald et al., 2009).
Sortilin, a member of the sorting receptor family that transport intracellular proteins, regulates GSK3-beta, beta-catenin and Twist pathway activation to induce epithelial-mesenchymal transition and glioblastoma invasion (Yang et al., 2019).
Response-response Relationship
GSK3beta inhibition by 1 mM of SB216763 or 5 mM of BRD3731 results in the decreased phosphorylation and stabilization of beta-catenin (Stump et al., 2019). The level of beta-catenin is increased by the inhibition of GSK3beta kinase activity (Stump et al., 2019). GSK3beta inhibition by small interference RNA (siRNA) of GSK3beta results in the decreased phosphorylation and increased expression of beta-catenin (Stump et al., 2019).
Time-scale
The treatment with SB216763 or BRD3731, GSK3beta inhibitors, decreases phosphorylated beta-catenin and increased beta-catenin expression in 48 hours (Stump et al., 2019). The cells are treated with GSK3beta small interference RNA (siRNA) for 48 hours to silence the expression of GSK3beta, which results in the activation of beta-catenin pathway (Stump et al., 2019).
Known Feedforward/Feedback loops influencing this KER
Beta-catenin is required and sufficient for the sequestration of GSK3 in acidic cytoplasmic endosomes (Taelman et al., 2010). Beta-catenin, of which level increases in Wnt signaling, facilitates GSK3 sequestration leading to feed-forward loop formation (Taelman et al., 2010).
GSK3-beta inhibition induced beta-catenin activation in human lung lymphatic endothelial cells (Homo sapiens) (Stump et al., 2019).